People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Liquid BioScience, Inc. | — | Biotechnology | Series B | $40.0M | $1.6B | 2017 |
| NeuBase Therapeutics, Inc. | — | Biotechnology | Series A | $17.1M | $42.8M | 2023 |
Franklyn Prendergast at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Franklyn Prendergast on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dov Goldstein | 1 | 6 |
| Matthew Nunez | 1 | 4 |
| Dietrich Stephan | 1 | 4 |
| Ira Greenstein | 1 | 3 |
| Patrick Lilley | 1 | 3 |
| Eric Richman | 1 | 2 |
| Dennis Kogod | 1 | 2 |
| June Almenoff | 1 | 2 |
| Thomas Riedhammer | 1 | 2 |
| Irach Taraporewala | 1 | 2 |
| Barry Straube | 1 | 1 |
| Andrew Limpert | 1 | 1 |
| Orin Hirschman | 1 | 1 |
| Sam Backenroth | 1 | 1 |
| Todd Branning | 1 | 1 |
| Gerald McDougall | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.